Companies › River 3 Renal
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| R3R01 ATP-binding cassette transporter A1 (ABCA1) inducer that increases efflux of cholesterol f | ABCA1 | Phase 2 | Diabetic Kidney Disease | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06600412 | R3R01 | Phase 2 | Diabetic Kidney Disease | Metabolic and endocrine | Apr 2027 |
–
Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International Extend Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.